文献速递肝病消化道肿瘤与早癌

酒精性肝硬化患者肝细胞癌发病率的估计

Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
PubMed 文献 · J Hepatol · 2018-08-06

CIRRAL队列在法国和比利时22个中心前瞻性纳入652例活检证实的代偿性酒精性肝硬化患者,中位随访29个月,肝细胞癌发病率为每100患者年2.9例,1年和2年累积发病率分别为1.8%和5.2%。43例肝细胞癌中33例(77%)符合米兰标准,但仅24例(56%)接受根治性治疗。

要点

  • 活检证实的代偿性酒精性肝硬化患者肝细胞癌发病率为每100患者年2.9例。
  • 1年和2年肝细胞癌累积发病率分别为1.8%和5.2%。
  • 43例肝细胞癌中33例(77%)符合米兰标准,仅24例(56%)接受根治性治疗。

核心结论

  • 大型前瞻性队列显示酒精性肝硬化患者肝细胞癌年发病率高达每100患者年2.9例,提示监测可能具有成本效益。
  • 检出肝细胞癌中符合米兰标准的比例高,但仅半数被转诊接受根治性治疗。
  • 两年死亡率高达7%。

研究设计与样本

  • CIRRAL队列为前瞻性研究,纳入活检证实的代偿性酒精性肝硬化患者。
  • 2010年10月至2016年4月,在22个法国和比利时中心共纳入652例患者,中位随访29个月。

主要发现

  • 随访期间43例患者诊断为肝细胞癌。
  • 肝细胞癌发病率为每100患者年2.9例,1年和2年累积发病率分别为1.8%和5.2%。
  • 43例肝细胞癌中33例(77%)符合米兰标准,仅24例(56%)接受根治性治疗。
  • 探索性预后分析显示年龄、男性、基线甲胎蛋白、胆红素和凝血酶原与肝细胞癌发生风险显著相关。
  • 73例死亡中61例有记录死因,27例直接归因于肝病;2年总生存率、无事件生存率和肝病相关死亡累积发生率分别为93%(95%CI 90.5-95.4)、80.3%(95%CI 76.9-83.9)和3.2%(95%CI 1.6-4.8)。

临床怎么用

  • 作者认为酒精相关肝病患者不应被排除在肝细胞癌监测之外。

局限性

  • 连续入组患者的不确定性限制了结果。
  • 存在较大比例脱落(153/652)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: More than 90% of cases of hepatocellular carcinoma (HCC) occur in patients with cirrhosis, of which alcohol is a major cause. The CIRRAL cohort aimed to assess the burden of complications in patients with alcoholic cirrhosis, particularly the occurrence of HCC. METHODS: Patients with biopsy-proven compensated alcoholic cirrhosis were included then prospectively followed. The main endpoint was the incidence of HCC. Secondary outcomes were incidence of hepatic focal lesions, overall survival (OS), liver-related mortality and event-free survival (EFS). RESULTS: From October 2010 to April 2016, 652 patients were included in 22 French and Belgian centers. During follow-up (median 29 months), HCC was diagnosed in 43 patients. With the limitation derived from the uncertainty of consecutive patients' inclusion and from a sizable proportion of dropouts (153/652), the incidence of HCC was 2.9 per 100 patient-years, and one- and two-year cumulative incidences of 1.8% and 5.2%, respectively. Although HCC fulfilled the Milan criteria in 33 cases (77%), only 24 patients (56%) underwent curative treatment. An explorative prognostic analysis showed that age, male gender, baseline alpha-fetoprotein, bilirubin and prothrombin were significantly associated with the risk of HCC occurrence. Among 73 deaths, 61 had a recorded cause and 27 were directly attributable to liver disease. At two years, OS, EFS and cumulative incidences of liver-related deaths were 93% (95% CI 90.5-95.4), 80.3% (95% CI 76.9-83.9), and 3.2% (95% CI 1.6-4.8) respectively. CONCLUSION: This large prospective cohort incompletely representative of the whole population with alcoholic cirrhosis showed: a) an annual incidence of HCC of up to 2.9 per 100 patient-years, suggesting that surveillance might be cost effective in these patients; b) a high proportion of HCC detected within the Milan criteria, but only one-half of detected HCC cases were referred for curative treatments; c) a two-year mortality rate of up to 7%. LAY SUMMARY: Cirrhosis is a risk factor for primary liver cancer, leading to recommendations for periodic screening. However, for alcohol-related liver disease the rational of periodic screening for hepatocellular carcinoma (HCC) is controversial, as registry and databased studies have suggested a low incidence of HCC in these patients and highly competitive mortality rates. In this study, a large cohort of patients with biopsy-proven alcoholic cirrhosis prospectively screened for HCC demonstrated a high annual incidence of HCC (2.9%) and a high percentage of small cancers theoretically eligible for curative treatment. This suggests that patients with liver disease related to alcohol should not be ruled out of screening.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ganne-Carrié N, Chaffaut C, Bourcier V, et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol. 2018. PMID: 30092234. doi:10.1016/j.jhep.2018.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。